Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Tumors   Cancer prone   Deep Insight   Case Reports   Portal   Journals   Teaching
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

 

Cytogenetic / Clinical Entities

Table of Content

1. Chronic Myeloproliferative Diseases (MPD)

+13 or trisomy 13
+14 or trisomy 14 (solely)
+16 or trisomy 16 (solely)
+20 or trisomy 20 (solely)
+6 or trisomy 6
+8 or trisomy 8
+9 or trisomy 9
-21 or monosomy 21 (solely)
15q13-15 Rearrangements
1q translocations (unbalanced) in myeloid malignancies
1q triplication in hematologic malignancies
3q26 rearrangements (MECOM) in myeloid malignancies
8p11 myeloproliferative syndrome (FGFR1)
Agnogenic myeloid metaplasia
Agnogenic myeloid metaplasia
Atypical Chronic Myeloid Leukemia (aCML)
Chronic myelogenous leukaemia (CML)
Essential Thrombocythemia (ET)
Idiopathic myelofibrosis
Idiopathic myelofibrosis.
Isolated tetrasomy 8 in AML, MDS and MPD
Juvenile Chronic Myelogenous Leukemia (JCML)
Monosomal karyotype (MK) in myeloid malignancies
Myelofibrosis with Myeloid Metaplasia (MMM).
Polycythemia Vera (PV)
Y loss in leukemia
del (13q)
del(13q) in myeloid malignancies
del(16)(q22) CBFB/MYH11
del(20q) in myeloid malignancies
del(9q) solely
der(6)t(1;6)(q21-23;p21)
der(9;18)(p10;q10)
dic(1;15)(p11;p11)
i(17q) solely in myeloid malignancies
idic(X)(q13)
ins(12;8)(p11;p12p22) FGFR1OP2/FGFR1
ins(3;3)(q26;q21q26) PSMD2/MECOM
ins(9;4)(q33;q12q25) CDK5RAP2/PDGFRA
inv(11)(p15q22) NUP98/DDX10
inv(16)(p13q22) CBFB/MYH11
inv(3)(p12q26) ?/MECOM
inv(3)(q21q26) PSMD2/MECOM
inv(3)(q23q26) ?/MECOM
t(10;12)(q24;p13) ETV6/GOT1
t(11;11)(p15;q22) NUP98/DDX10
t(11;21)(q13;q22) RUNX1/MACROD1
t(12;13)(p12;q12-14) ETV6/CDX2
t(12;13)(p13;q12) ETV6/FLT3
t(12;13)(p13;q14) LIN00598/ETV6
t(12;22)(p13;q12) MN1/ETV6
t(16;16)(p13;q22) CBFB/MYH11
t(1;12)(p36;p13) ETV6/MDS2
t(1;12)(q21;p13) ETV6/ARNT
t(1;18)(q10;q10)
t(1;3)(p36;p21)
t(1;3)(p36;q21) PSMD2/PRDM16
t(1;5)(q22;q33) PDE4DIP/PDGFRB
t(1;7)(q10;p10)
t(2;11)(q31;p15) NUP98/HOXD11
t(2;11)(q31;p15) NUP98/HOXD13
t(2;13)(p16;q12) SPTBN1/FLT3
t(2;3)(p15-23;q26-27) ?/MECOM
t(2;3)(p15-23;q26-27) ?/MECOM
t(2;4)(p22;q12) STRN/PDGFRA
t(2;4)(p23;q25-q35)
t(2;5)(p21;q33) SPTBN1/PDGFRB
t(3;11)(q26;p15) ?/MECOM
t(3;12)(q26;p13) ETV6/EVI1
t(3;12)(q26;p13) ETV6/MECOM
t(3;17)(q26;q22) ?/MECOM
t(3;21)(q26;q22) RUNX1/MECOM
t(3;3)(q21;q26) PSMD2/MECOM
t(3;5)(q21;q31)
t(3;5)(q25;q34) NPM1/MLF1
t(3;7)(q26;q21) MECOM/CDK6
t(4;10)(q12;p11) KIF5B/PDGFRA
t(4;12)(q12;p13) PDGFRA/ETV6
t(4;21)(q35;q22) RUNX1/?
t(4;22)(q12;q11.2) BCR/PDGFRA
t(4;5)(q21;q33) PRKG2/PDGFRB
t(5;10)(q33;q21) CCDC6/PDGFB
t(5;11)(q31;q23) KMT2A/ARHGAP26
t(5;11)(q33;p13) CAPRIN1/PDGFRB
t(5;12)(q31;p13) ETV6/ACSL6 in MDS,AML and AEL
t(5;12)(q33;p13) ETV6/PDGFRB
t(5;12)(q33;q24) GIT2/PDGFRB
t(5;14)(q33;q24) NIN/PDGFRB
t(5;14)(q33;q32) PDGFRB/CCDC88C
t(5;15)(q33;q22) TP53BP1/PDGFRB
t(5;9)(q32;p24) KANK1/PDGFRB
t(6;20)(q13;q12) LMBRD1/CHD6
t(7;11)(p15;p15) NUP98/HOXA9
t(7;14)(q21;q13)
t(7;17)(p15;q23) MSI2/HOXA9
t(7;17)(q32-34;q23) MSI2/?
t(7;8)(q34;p11) TRIM24/FGFR1
t(8;12)(p12;p11) FGFR1OP2/FGFR1
t(8;12)(p12;q15) CPSF6/FGFR1
t(8;12)(q22;q13) HMGA2/?
t(8;14)(q11;q32) IGH/CEBPD
t(8;17)(p11;q23) MYO18A/FGFR1
t(8;17)(p11;q25) ?/FGFR1
t(8;17)(q13;q23)
t(8;22)(p11;q11) BCR/FGFR1
t(8;9)(p12;q33) CNTRL/FGFR1
t(9;11)(p22;p15) NUP98/PSIP1
t(9;12)(p24;p13) ETV6/JAK2
t(9;12)(q34;p13) ETV6/ABL1
t(9;14)(q33;q32) IGH/LHX2
t(9;22)(p24;q11.2)
t(9;22)(q34;q11) BCR/ABL1 in CML
t(X;20)(q13;q13.3)
t(X;21)(p11;q22) RUNX1/?
t(Y;1)(q12;q12)

2. Myelodysplastic Syndromes (MDS)

+11 or trisomy 11 (solely) KTM2A
+13 or trisomy 13
+14 or trisomy 14 (solely)
+15 or trisomy 15 (as sole autosomal abnormality)
+16 or trisomy 16 (solely)
+18 or trisomy 18 in lymphoproliferative disorders
+20 or trisomy 20 (solely)
+21 or trisomy 21
+6 or trisomy 6
+7 or trisomy 7 (solely)
+8 or trisomy 8
+9 or trisomy 9
-21 or monosomy 21 (solely)
-7/del(7q) in adults
-7/del(7q) in childhood
11q23 rearrangements (KMT2A) in leukaemia
12p abnormalities in myeloid malignancies
1q translocations (unbalanced) in myeloid malignancies
1q triplication in hematologic malignancies
3q26 rearrangements (MECOM) in myeloid malignancies
Atypical Chronic Myeloid Leukemia (aCML)
Childhood myelodysplastic syndromes
Classification of myelodysplasic syndromes
Congenital leukaemias
Infant leukaemias
Isolated tetrasomy 8 in AML, MDS and MPD
MLL amplification in leukemia
Monosomal karyotype (MK) in myeloid malignancies
Neonatal leukaemias
Refractory anemia (RA)
Refractory anemia with excess blasts (RAEB)
Refractory anemia with ringed sideroblasts (RARS)
Trisomy 19
Trisomy 2
Y loss in leukemia
del (13q)
del(13q) in myeloid malignancies
del(16)(q22) CBFB/MYH11
del(17p) in myeloid malignancies
del(20q) in myeloid malignancies
del(21)(q21q22) USP16/RUNX1
del(5q) in myeloid neoplasms
del(9q) solely
dic(17;20)(p11.2;q11.2)
dic(1;15)(p11;p11)
i(17q) solely in myeloid malignancies
i(5)(p10) in acute myeloid leukemia
ider(20q) in Myeloid Malignancies
idic(X)(q13)
ins(3;3)(q26;q21q26) PSMD2/MECOM
inv(11)(p15q22) NUP98/DDX10
inv(11)(q21q23) KMT2A/MAML2 in therapy related leukemias
inv(12)(p13q15) ETV6/PTPRR
inv(16)(p13q22) CBFB/MYH11
inv(18)(p11q21)
inv(3)(q21q26) PSMD2/MECOM
inv(6)(p15q13)
inv(6)(p25q13)
t(10;12)(q24;p13) ETV6/GOT1
t(10;16)(q22;p13) KAT6B/CREBBP
t(11;11)(p15;q22) NUP98/DDX10
t(11;16)(q23;p13.3) KTM2A/CREBBP
t(11;17)(q23;q25) KTM2A/SEPT9
t(11;20)(p15;q11) NUP98/TOP1
t(11;21)(q13;q22) RUNX1/MACROD1
t(12;12)(p13;q13) ETV6/BAZ2A
t(12;12)(p13;q13) HMGA2/?
t(12;13)(p12;q12-14) ETV6/CDX2
t(12;13)(p13;q14) LIN00598/ETV6
t(12;14)(q13;q31) HMGA2/?
t(12;17)(p13;p13) ETV6/PER1
t(12;18)(p13;q12) ETV6/SETBP1
t(12;20)(q15;q11.2) HMGA2 truncated
t(12;22)(p13;q12) MN1/ETV6
t(14;21)(q22;q22) RUNX1/?
t(15;21)(q22;q22) RUNX1/?
t(16;16)(p13;q22) CBFB/MYH11
t(16;21)(q24;q22) RUNX1/CBFA2T3
t(1;11)(p32;q23) KMT2A/EPS15
t(1;12)(p36;p13) ETV6/MDS2
t(1;12)(q21;p13) ETV6/ARNT
t(1;12)(q21;q24)
t(1;16)(q11;q11)
t(1;18)(q10;q10)
t(1;19)(p13;p13.1)
t(1;2)(p36;p21) PRDM16 and LINC00982/?
t(1;21)(p36;q22) RUNX1/PRDM16
t(1;3)(p36;p21)
t(1;3)(p36;q21) PSMD2/PRDM16
t(1;6)(p36;p21)
t(1;7)(q10;p10)
t(20;21)(q13.2;q22.12) ZFP64/RUNX1
t(20;21)(q13;q22) RUNX1/?
t(2;11)(p21;q23) KMT2A/?
t(2;11)(q31;p15) NUP98/HOXD11
t(2;11)(q31;p15) NUP98/HOXD13
t(2;12)(q31;p13) ETV6/?
t(2;3)(p15-23;q26-27) ?/MECOM
t(2;3)(p15-23;q26-27) ?/MECOM
t(2;4)(p23;q25-q35)
t(3;11)(p25;p15) ANKRD28/NUP98
t(3;11)(q12;p15) NUP98/LNP1
t(3;12)(q26;p13) ETV6/EVI1
t(3;12)(q26;p13) ETV6/MECOM
t(3;16)(q21;q22)
t(3;18)(q26;q11) ?/MECOM
t(3;21)(q26;q22) RUNX1/MECOM
t(3;3)(p24;q26) ?/MECOM
t(3;3)(q21;q26) PSMD2/MECOM
t(3;4)(p21;q34)
t(3;5)(q21;q31)
t(3;5)(q25;q34) NPM1/MLF1
t(3;8)(q26;q24) PVT1/MECOM
t(4;11)(p12;q23) KMT2A/FRYL
t(4;17)(q12;q21) FIP1L1/RARA
t(4;5)(q31;q31)
t(5;11)(q31;q23) KMT2A/ARHGAP26
t(5;12)(q13;p13) ?/ETV6
t(5;12)(q31;p13) ETV6/ACSL6 in MDS,AML and AEL
t(5;12)(q33;p13) ETV6/PDGFRB
t(5;16)(q32;p13) NDE1/PDGFRB
t(5;17)(q33;p11.2) SPECC1/PDGFRB
t(5;17)(q33;p13) RABEP1/PDGFRB
t(5;21)(q13;q22) RUNX1/?
t(5;7)(q33;q11) HIP1/PDGFRB
t(6;12)(p21;p13) CCND3/ETV6 in lymphoid malignancies
t(6;20)(q13;q12) LMBRD1/CHD6
t(6;21)(p22;q22) RUNX1-?
t(6;8)(q27;p12) FGFR1OP/FGFR1
t(6;9)(p22;q34) DEK/NUP214
t(7;12)(p12;q13) HMGA2 truncated
t(7;12)(q36;p13) MNX1/ETV6
t(8;12)(q12;p13)
t(8;12)(q22;q13) HMGA2/?
t(8;13)(p11;q12) ZMYM2/FGFR1
t(8;21)(q23;q22) RUNX1/ZFPM2
t(8;9)(p22;p24) PCM1/JAK2
t(9;12)(p24;p13) ETV6/JAK2
t(9;12)(q22;p12) ETV6/SYK
t(9;12)(q34;p13) ETV6/ABL1
t(X;20)(q13;q13.3)
t(Y;1)(q12;q12)

3. Treatment Related Leukaemias (t-ANLL)

+11 or trisomy 11 (solely) KTM2A
+20 or trisomy 20 (solely)
+4 or trisomy 4
+8 or trisomy 8
-7/del(7q) in adults
-7/del(7q) in childhood
11p15 rearrangements (NUP98) in treatment related leukemia
11q23 rearrangements (KMT2A) in leukaemia
11q23 rearrangements (KMT2A) in therapy related leukaemias
12p abnormalities in myeloid malignancies
12p13 rearrangements (ETV6) in treatment related leukemia
21q22 rearrangements (RUNX1) in treatment related leukemia
3q21q26 rearrangements (RPN1/MECOM) in treatment related leukemia
Biphenotypic Acute Leukaemia (BAL)
Childhood myelodysplastic syndromes
Classification of acute myeloid leukemias
Classification of myelodysplasic syndromes
MLL amplification in leukemia
del(13q) in myeloid malignancies
del(16)(q22) CBFB/MYH11
del(17p) in myeloid malignancies
del(5q) in myeloid neoplasms
dic(17;20)(p11.2;q11.2)
inv(11)(q21q23) KMT2A/MAML2 in therapy related leukemias
inv(16)(p13q22) CBFB/MYH11
inv(16)(p13q22) CBFB/MYH11 in treatment related leukemia
inv(6)(p15q13)
t(10;11)(p12;q23) KMT2A/MLLT10
t(11;11)(q13;q23) KTM2A/ARHGEF17
t(11;12)(p15;q13) NUP98/?
t(11;12)(q23;q13) /HMGA2
t(11;14)(q23;q32) KTM2A/CEP170B
t(11;15)(q23;q14) KTM2A/CASC5
t(11;16)(q23;p13.3) KTM2A/CREBBP
t(11;17)(q23;p13) KTM2A/GAS7
t(11;17)(q23;q25) KTM2A/SEPT9
t(11;19)(q23;p13.1) KTM2A/ELL
t(11;19)(q23;p13.3) KTM2A/MLLT1
t(11;20)(p15;q11) NUP98/TOP1
t(11;22)(q23;q13) KTM2A/EP300
t(12;13)(p13;q14) LIN00598/ETV6
t(12;21)(q24;q22) RUNX1/?
t(14;21)(q22;q22) RUNX1/?
t(15;17)(q22;q21) in treatment related leukemia
t(15;17)(q24;q21) PML/RARA
t(15;21)(q22;q22) RUNX1/?
t(16;16)(p13;q22) CBFB/MYH11
t(16;21)(q24;q22) RUNX1/CBFA2T3
t(17;21)(q11.2;q22) RUNX1/?
t(18;21)(q21;q22) RUNX1/?
t(19;21)(q13.4;q22) RUNX1 truncated
t(1;11)(q23;p15) NUP98/PRRX1
t(1;12)(q21;q24)
t(1;21)(p22;q22) RUNX1/CLCA2
t(1;21)(p36;q22) RUNX1/PRDM16
t(1;3)(p36;p21)
t(1;3)(p36;q21) PSMD2/PRDM16
t(1;6)(p36;p21)
t(1;7)(p36;q34)
t(1;7)(q10;p10)
t(2;11)(q31;p15) NUP98/HOXD11
t(2;11)(q31;p15) NUP98/HOXD13
t(2;11)(q37;q23) KMT2A/SEPT2
t(2;19)(p11;p13)
t(2;3)(p15-23;q26-27) ?/MECOM
t(2;3)(p15-23;q26-27) ?/MECOM
t(2;8)(p23;p11) KAT6A/ASXL2
t(3;11)(p21;q23) KMT2A/NCKIPSD
t(3;11)(q25;q23) KMT2A/GMPS
t(3;11)(q28;q23) KMT2A/LPP
t(3;12)(q26;q21) ?/MECOM
t(3;17)(q26;q22) ?/MECOM
t(3;21)(q26;q22) RUNX1/MECOM
t(3;21)(q26;q22) RUNX1/MECOM in treatment related leukemia
t(3;6)(q25;q26) ?/MECOM
t(4;11)(p12;q23) KMT2A/FRYL
t(4;11)(q21;q23) KMT2A/AFF1
t(4;12)(q12;p13) CHIC2/ETV6
t(5;11)(q31;q23) KMT2A/ARHGAP26
t(6;11)(q27;q23) KMT2A/MLLT4
t(6;21)(p22;q22) RUNX1-?
t(6;9)(p22;q34) DEK/NUP214
t(8;16)(p11;p13) KAT6A/CREBBP
t(8;16)(p11;p13) KAT6A/CREBBP in treatment related leukemia
t(8;21)(q22;q22) RUNX1/RUNX1T1
t(8;21)(q22;q22) RUNX1/RUNX1T1 in treatment related leukemia
t(9;11)(p22;q23) KMT2A/MLLT3
t(9;21)(p22;q22)
t(9;22)(q34;q11) BCR/ABL1 in treatment related leukemia

4. Acute Non Lymphocytic Leukaemias (ANLL)
+10 or trisomy 10 (solely)
+11 or trisomy 11 (solely) KTM2A
+13 or trisomy 13
+13,+13 or tetrasomy 13
+14 or trisomy 14 (solely)
+15 or trisomy 15 (as sole autosomal abnormality)
+16 or trisomy 16 (solely)
+18 or trisomy 18 in lymphoproliferative disorders
+21 or trisomy 21
+22 or trisomy 22 (solely?)
+4 or trisomy 4
+6 or trisomy 6
+7 or trisomy 7 (solely)
+8 or trisomy 8
+9 or trisomy 9
-21 or monosomy 21 (solely)
-7/del(7q) in adults
-7/del(7q) in childhood
11q23 rearrangements (KMT2A) in de novo childhood acute myeloid leukemia
11q23 rearrangements (KMT2A) in leukaemia
12p abnormalities in myeloid malignancies
15q13-15 Rearrangements
1q translocations (unbalanced) in myeloid malignancies
1q triplication in hematologic malignancies
3q26 rearrangements (MECOM) in myeloid malignancies
Acute Erythroid leukaemias
Acute basophilic leukemia
Acute megakaryoblastic leukemia (AMegL)
Acute promyelocytic leukemia (APL)
Biphenotypic Acute Leukaemia (BAL)
Classification of acute myeloid leukemias
Congenital leukaemias
Infant leukaemias
Isolated tetrasomy 8 in AML, MDS and MPD
M0 acute non lymphocytic leukemia (M0-ANLL)
M3/M3v acute myeloid leukemia (AML M3/M3v)
M3/M3v acute non lymphocytic leukemia (M3-ANLL)
M7 acute non lymphocytic leukemia (M7-ANLL)
MLL amplification in leukemia
Monosomal karyotype (MK) in myeloid malignancies
Neonatal leukaemias
Systemic mast cell disease (SMCD)
Trisomy 19
Trisomy 2
Trisomy 5
Y loss in leukemia
del (13q)
del(11)(q23q23) KMT2A/ARHGEF12
del(11)(q23q23) KMT2A/CBL
del(16)(q22) CBFB/MYH11
del(17)(q21q24) PRKAR1A/RARA
del(17p) in myeloid malignancies
del(20q) in myeloid malignancies
del(21)(q21q22) USP16/RUNX1
del(5q) in myeloid neoplasms
del(9q) solely
dic(17;20)(p11.2;q11.2)
dic(1;15)(p11;p11)
dup(17)(q12q21) STAT5B/RARA
i(5)(p10) in acute myeloid leukemia
i(8)(q10) in acute myeloid leukaemia
ider(20q) in Myeloid Malignancies
idic(7)(q11.2)
idic(X)(q13)
ins(3;3)(q26;q21q26) PSMD2/MECOM
ins(X;11)(q26;q23q23)
inv(11)(p15q22) NUP98/DDX10
inv(12)(p13q15) ETV6/PTPRR
inv(14)(q11q32.1) TRA-TRD/TCL1A
inv(16)(p13q22) CBFB/MYH11
inv(16)(p13q24) CBFA2T3/GLIS2
inv(3)(q21q26) PSMD2/MECOM
inv(3)(q21q26) PSMD2/MECOM
inv(6)(p25q13)
inv(8)(p11q13) KAT6A/NCOA2
t(10;11)(p11.2;q23) KMT2A/ABI1
t(10;11)(p12;q23) KMT2A/MLLT10
t(10;11)(p13;q21) PICALM/MLLT10
t(10;11)(q22;q23) KMT2A/TET1
t(10;16)(q22;p13) KAT6B/CREBBP
t(10;17)(p15;q21) ZMYND11/MBTD1
t(11;11)(p15;q22) NUP98/DDX10
t(11;11)(q23;q23) KMT2A/CBL
t(11;12)(p15;p13) NUP98/KDM5A
t(11;12)(q23;q13) KTM2A/SARNP
t(11;16)(q23;p13.3) KTM2A/CREBBP
t(11;17)(p15;p13) NUP98/PHF23
t(11;17)(q13;q21) NUMA1/RARA
t(11;17)(q23;p13) KTM2A/GAS7
t(11;17)(q23;q12) KTM2A/RARA
t(11;17)(q23;q12-21) KMT2A/LASP1
t(11;17)(q23;q12-21) KMT2A/MMLT6
t(11;17)(q23;q21) ZBTB16/RARA
t(11;17)(q23;q25) KTM2A/SEPT9
t(11;19)(q23;p13.1) KTM2A/ELL
t(11;19)(q23;p13.3) KTM2A/MLLT1
t(11;20)(p15;q11) NUP98/TOP1
t(11;21)(q13;q22) RUNX1/MACROD1
t(11;21)(q21;q22) RUNX1/LPXN
t(11;22)(q23;q11.2) KTM2A/SEPT5
t(12;12)(p13;q13) ETV6/BAZ2A
t(12;13)(p12;q12-14) ETV6/CDX2
t(12;13)(p13;q14) LIN00598/ETV6
t(12;15)(p13;q25) ETV6/NTRK3
t(12;17)(p11;q11) in AML
t(12;17)(p13;p13) ETV6/PER1
t(12;17)(p13;q11) TAF15/ZNF384
t(12;18)(p13;q12) ETV6/SETBP1
t(12;19)(q13;q13)
t(12;21)(q12;q22) RUNX1 truncated
t(12;22)(p13;q12) EWSR1/ZNF384
t(12;22)(p13;q12) MN1/ETV6
t(14;14)(q11;q32.1) TRA-TRD/TCL1A
t(14;22)(q32;q11) IGH/IGL
t(15;17)(q24;q21) PML/RARA
t(16;16)(p13;q22) CBFB/MYH11
t(16;21)(p11;q22) FUS/ERG
t(16;21)(q24;q22) RUNX1/CBFA2T3
t(17;17)(q21;q21) STAT5B/RARA
t(17;17)(q21;q24) PRKAR1A/RARA
t(17;21)(q11.2;q22) RUNX1/?
t(1;11)(p32;q23) KMT2A/EPS15
t(1;11)(q21;q23) KMT2A/MLLT11
t(1;12)(q21;q24)
t(1;12)(q25;p13) ETV6/ABL2
t(1;14)(q25;q32) IGH/LHX4
t(1;16)(q12;q24)
t(1;18)(q25;q23)
t(1;19)(p13;p13.1)
t(1;19)(q23;p13) TCF3/PBX1
t(1;2)(q12;q37)
t(1;21)(p32;q22) RUNX1/?
t(1;21)(p35;q22) RUNX1/YTHDF2
t(1;21)(p36;q22) RUNX1/PRDM16
t(1;21)(q12;q22) RUNX1/?
t(1;21)(q21;q22) RUNX1/ZNF687
t(1;22)(p13;q13) RBM15/MKL1
t(1;3)(p36;p21)
t(1;3)(p36;q21) PSMD2/PRDM16
t(1;7)(p36;q34)
t(1;7)(q10;p10)
t(1;8)(p22-p32;q22-q23)
t(20;21)(q11;q22) RUNX1/?
t(20;21)(q13;q22) RUNX1/?
t(2;11)(p21;q23) KMT2A/?
t(2;11)(q31;p15) NUP98/HOXD11
t(2;11)(q31;p15) NUP98/HOXD13
t(2;11)(q37;q23) KMT2A/SEPT2
t(2;14)(p13-16;q32) IGH/BCL11A
t(2;19)(p11;p13)
t(2;21)(p11;q22) RUNX1/?
t(2;3)(p15-23;q26-27) ?/MECOM
t(2;3)(p16;q26) BCL11A/MECOM
t(2;3)(p21;q26) THADA/MECOM
t(2;4)(p23;q25-q35)
t(3;11)(p25;p15) ANKRD28/NUP98
t(3;11)(q12;p15) NUP98/LNP1
t(3;11)(q13.13;q23) KMT2A/KIAA1524
t(3;12)(q26;p13) ETV6/EVI1
t(3;12)(q26;p13) ETV6/MECOM
t(3;16)(q21;q22)
t(3;17)(q26;q22) ?/MECOM
t(3;21)(p12;q22) RUNX1/?
t(3;21)(q26;q22) RUNX1/MECOM
t(3;3)(q21;q26) PSMD2/MECOM
t(3;4)(p21;q34)
t(3;5)(p21;q32) RBM6/CSF1R
t(3;5)(q21;q31)
t(3;5)(q25;q34) NPM1/MLF1
t(3;5)(q26;q34) ?/MECOM
t(3;6)(q25;q26) ?/MECOM
t(3;7)(q26;q21) MECOM/CDK6
t(3;8)(q21;q24) in myeloid malignancies
t(3;8)(q26;q24) PVT1/MECOM
t(4;11)(q21;q23) KMT2A/AFF1
t(4;11)(q35;q23) KMT2A/SORBS2
t(4;12)(q12;p13) CHIC2/ETV6
t(4;21)(q31;q22) RUNX1/SH3D19
t(4;5)(q31;q31)
t(5;11)(q31;q23) KMT2A/ARHGAP26
t(5;11)(q35;p15.5) NUP98/NSD1
t(5;11)(q35;q12) NSD1/FEN1
t(5;12)(p13;p13) NIPBL/ETV6
t(5;12)(q13;p13) ?/ETV6
t(5;12)(q31;p13) ETV6/ACSL6 in MDS,AML and AEL
t(5;12)(q33;p13) ERC1/PDGFRB
t(5;14)(q33;q32) PDGFRB/TRIP11
t(5;14)(q35;q11) TRD/NKX2-5
t(5;16)(q33;q22)
t(5;17)(q35;q21) NPM1/RARA
t(5;21)(q13;q22) RUNX1/?
t(6;11)(q13;q23) KMT2A-SMAP1
t(6;11)(q15;q23) KMT2A/?
t(6;11)(q27;q23) KMT2A/MLLT4
t(6;14)(q25-27;q32) BCL11B/?
t(6;20)(q13;q12) LMBRD1/CHD6
t(6;22)(p21;q11)
t(6;8)(q27;p12) FGFR1OP/FGFR1
t(6;9)(p22;q34) DEK/NUP214
t(7;11)(p15;p15) NUP98/HOXA9
t(7;12)(q36;p13) MNX1/ETV6
t(7;14)(q21;q13)
t(7;14)(q22;q11)
t(7;14)(q35;q32.1) TRB/TCL1A
t(7;21)(p15;q22) RUNX1/?
t(7;21)(p22;q22) RUNX1/USP42
t(7;8)(q34;p11) TRIM24/FGFR1
t(8;11)(p11;p15) NUP98/WHSC1L1
t(8;11)(p12;p15) ?/FGFR1
t(8;12)(q12;p13)
t(8;12)(q13;p13) ETV6/NCOA2
t(8;16)(p11;p13) KAT6A/CREBBP
t(8;19)(p11;q13) ERVK-6/FGFR1
t(8;19)(p11;q13) KAT6A/?
t(8;20)(p11;q13) KAT6A/NCOA3
t(8;21)(q22;q22) RUNX1/RUNX1T1
t(8;21)(q24;q22) RUNX1/TRPS1
t(8;22)(p11;q13) KAT6A/EP300
t(8;9)(p22;p24) PCM1/JAK2
t(9;11)(p22;p15) NUP98/PSIP1
t(9;11)(p22;q23) KMT2A/MLLT3
t(9;11)(q34;p15) NUP98/PRRX2
t(9;11)(q34;q23) FNBP1/KMT2A
t(9;11)(q34;q23) KMT2A/DAB2IP
t(9;12)(q34;p13) ETV6/ABL1
t(9;21)(q34;q22) RUNX1 truncated
t(9;22)(q34;q11) BCR/ABL1 in AML
t(9;9)(q34;q34) SET/NUP214
t(X;10)(p10;p10)
t(X;11)(q13;q23) KMT2A/FOXO4
t(X;11)(q22;q23) KMT2A/?
t(X;11)(q24;q23) KMT2A/SEPT6
t(X;11)(q26;q23)
t(X;17)(p11;q21) BCOR/RARA
t(X;21)(p22;q22) RUNX1/RPL22
t(X;21)(q26;q22) ELF4/ERG
t(X;6)(p11;q23) MYB/GATA1

5. B-Cell Acute Lymphocytic Leukaemias (B-ALL)
+10 or trisomy 10 (solely)
+13 or trisomy 13
+15 or trisomy 15 (as sole autosomal abnormality)
+16 or trisomy 16 (solely)
+18 or trisomy 18 in lymphoproliferative disorders
+21 or trisomy 21
+4 or trisomy 4
+6 or trisomy 6
+8 or trisomy 8
+9 or trisomy 9
-21 or monosomy 21 (solely)
11q23 rearrangements (KMT2A) in childhood acute lymphoblastic leukemia
11q23 rearrangements (KMT2A) in leukaemia
12p rearrangements (ETV6) in ALL
15q13-15 Rearrangements
9p Rearrangements in ALL
Biphenotypic Acute Leukaemia (BAL)
Congenital leukaemias
High hyperdiploid acute lymphoblastic leukaemia
Infant leukaemias
Near haploid acute lymphoblastic leukaemia
Neonatal leukaemias
Severe hypodiploid acute lymphoblastic leukaemia
Trisomy 5
del(13q) in ALL
del(6q) abnormalities in lymphoid malignancies
del(9)(p13p24) PAX5/JAK2
dic(3;9)(p14;p13) PAX5/FOXP1
dic(7;9)(p11-12;p12-13) PAX5/LOC392027
dic(7;9)(p11-13;p11)
dic(9;12)(p13;p12) PAX5/SLCO1B3
dic(9;12)(p13;p13) PAX5/ETV6
dic(9;16)(p13;q11) PAX5/
dic(9;17)(p13;q11) PAX5/TAOK1
dic(9;18)(p13;q11) PAX5/ZNF521
dic(9;20)(p11-13;q11) PAX5/Various
dup(21q) amplified (RUNX1)
i(6)(p10)
i(9q) in ALL
ins(5;11)(q31;q13q23) KMT2A/AFF4
ins(X;11)(q26;q23q23)
inv(11)(q13q23) KMT2A/BTBD18
inv(14)(q11q32) CEBPE/IGH
inv(14)(q11q32.1) TRA-TRD/TCL1A
inv(19)(p13q13) TCF3/TFPT
inv(9)(p13p24) PAX5/JAK2
t(10;11)(p12;q23) KMT2A/MLLT10
t(10;11)(p13;q21) PICALM/MLLT10
t(11;16)(q23;p13.3) KTM2A/CREBBP
t(11;17)(q23;p13) KTM2A/GAS7
t(11;17)(q23;q25) KTM2A/SEPT9
t(11;19)(q23;p13.3) KMT2A/ACER1
t(11;19)(q23;p13.3) KTM2A/MLLT1
t(11;20)(q23;q11) KTM2A/MAPRE1
t(12;12)(p13;q13) ETV6/BAZ2A
t(12;13)(p12;q12-14) ETV6/CDX2
t(12;13)(p13;q14) LIN00598/ETV6
t(12;14)(p13;q32) IGH/ETV6
t(12;17)(p13;q11) TAF15/ZNF384
t(12;17)(p13;q11-21) in ALL
t(12;19)(p13;p13) TCF3/ZNF384
t(12;21)(p13;q22) ETV6/RUNX1
t(12;22)(p13;q12) EWSR1/ZNF384
t(13;19)(q14;p13) TCF3/?
t(14;14)(q11;q32) CEBPE/IGH
t(14;14)(q11;q32.1) TRA-TRD/TCL1A
t(14;18)(q32;q21) IGH/BCL2
t(14;19)(q32;q13) IGH/CEBPA
t(14;20)(q32;q13) IGH/CEBPA
t(17;19)(q22;p13) TCF3/HLF
t(18;22)(q21;q11) IGL/BCL2
t(19;19)(p13;q13) TCF3/TFPT
t(1;11)(p32;q23) KMT2A/EPS15
t(1;14)(q21;q32)
t(1;14)(q21;q32) BCL9/IGH
t(1;14)(q25;q32) IGH/LHX4
t(1;18)(q25;q23)
t(1;19)(q23;p13) TCF3/PBX1
t(1;2)(q12;q37)
t(1;22)(q21;q11)
t(1;22)(q21;q11) IGL/BCL9
t(1;3)(p36;p21)
t(1;5)(q22;q33) PDE4DIP/PDGFRB
t(1;9)(p13;p12) PAX5/HIPK1
t(1;9)(p34;q34) SFPQ/ABL1
t(1;9)(q24;q34) RCSD1/ABL1
t(2;11)(p21;q23) KMT2A/?
t(2;14)(p13-16;q32) IGH/BCL11A
t(2;18)(p11;q21) IGK/BCL2
t(2;8)(p12;q24) IGK/MYC
t(2;9)(p11;p13) PAX5/?
t(2;9)(q37;q34) INPP5D-ABL1
t(3;11)(q21;q23) KMT2A/EEFSEC
t(4;11)(p12;q23) KMT2A/FRYL
t(4;11)(q21;q23) KMT2A/AFF1
t(4;12)(q12;p13) CHIC2/ETV6
t(5;11)(q31;q23) KMT2A/ARHGAP26
t(5;14)(q31;q32) IGH/IL3
t(5;15)(p15;q11-13)
t(6;12)(p21;p13) CCND3/ETV6 in lymphoid malignancies
t(6;14)(p22;q32) IGH/ID4
t(6;14)(q25-27;q32) BCL11B/?
t(6;22)(p21;q11)
t(7;12)(q36;p13) MNX1/ETV6
t(7;14)(q35;q32.1) TRB/TCL1A
t(7;9)(q11.2;p13.2) PAX5/AUTS2
t(7;9)(q11;p12) PAX5/POM121
t(7;9)(q11;p13) PAX5/ELN
t(8;12)(q13;p13) ETV6/NCOA2
t(8;14)(q11;q32) IGH/CEBPD
t(8;14)(q24;q11) TRA/MYC
t(8;14)(q24;q32) IGH/MYC
t(8;22)(q24;q11) IGL/MYC
t(8;9)(p22;p24) PCM1/JAK2
t(8;9)(q24;p13) ?/MYC
t(8;9)(q24;q13)
t(9;10)(q34;q22) ZMIZ1/ABL1
t(9;12)(p24;p13) ETV6/JAK2
t(9;12)(q34;p13) ETV6/ABL1
t(9;13)(p12;q21) PAX5/DACH1
t(9;15)(p13;q24) PAX5/PML
t(9;22)(p13;q13) PAX5/BRD1
t(9;22)(q34;q11) BCR/ABL1 in ALL
t(9;9)(p13;p24) PAX5/JAK2
t(X;11)(q22;q23) KMT2A/?
t(X;11)(q26;q23)
t(X;9)(q21;p13) PAX5/DACH2

6. T-Cell Acute Lymphocytic Leukaemias (T-ALL)
+20 or trisomy 20 (solely)
+4 or trisomy 4
+7 or trisomy 7 (solely)
+8 or trisomy 8
+9 or trisomy 9
11q23 rearrangements (KMT2A) in childhood acute lymphoblastic leukemia
11q23 rearrangements (KMT2A) in leukaemia
12p rearrangements (ETV6) in ALL
15q13-15 Rearrangements
1p32 rearrangements
9p Rearrangements in ALL
Biphenotypic Acute Leukaemia (BAL)
NK cell neoplasias
NUP214/ABL1 fusion gene on amplified episomes
T-lineage acute lymphoblastic leukemia (T-ALL)
del(11)(p12p13) LMO2
del(13q) in ALL
del(6q) abnormalities in lymphoid malignancies
del(9q) solely
dic(9;12)(p13;p13) PAX5/ETV6
i(6)(p10)
inv(14)(q11q32.1) TRA-TRD/TCL1A
inv(7)(p15q34) TRB/HOXA10
t(10;11)(p13;q21) PICALM/MLLT10
t(10;11)(q25;p15) NUP98/ADD3
t(10;14)(q24;q11) TRD/TLX1
t(11;14)(p13;q11) TRD/LMO2
t(11;14)(p15;q11) TRD/LMO1
t(11;18)(p15;q12) NUP98/SETBP1
t(11;19)(q23;p13.3) KTM2A/MLLT1
t(12;12)(p13;q13) ETV6/BAZ2A
t(12;13)(p12;q12-14) ETV6/CDX2
t(12;14)(p13;q11) TRA or TRD/CCND2
t(14;14)(q11;q32.1) TRA-TRD/TCL1A
t(14;21)(q11;q22) TRA/OLIG2
t(1;12)(q21;p13) ETV6/ARNT
t(1;14)(p32;q11) TRA/TAL1
t(1;19)(q23;p13) TCF3/PBX1
t(1;2)(p36;p21) PRDM16 and LINC00982/?
t(1;3)(p32;p21) TCTA/TAL1
t(1;5)(p32;q31) ?/TAL1
t(1;7)(p32;q34) TRB/TAL1
t(1;7)(p34;q34) TRB/LCK
t(2;14)(p13-16;q32) IGH/BCL11A
t(2;21)(q11;q22)
t(3;11)(q12;p15) NUP98/LNP1
t(3;11)(q29;p15) NUP98/IQCG
t(4;11)(q21;p15) NUP98/RAP1GDS1
t(4;11)(q21;q23) KMT2A/AFF1
t(4;21)(q31;q22) RUNX1/?
t(5;12)(q13;p13) ?/ETV6
t(5;14)(q35;q11) TRD/NKX2-5
t(5;14)(q35;q32) BCL11B/TLX3
t(5;14)(q35;q32.2) BCL11B/TLX3 and NKX2-5
t(5;17)(q13;q21)
t(5;6)(q33-34;q23) CEP85L/PDGFRB
t(5;7)(q35;q21) TLX3/CDK6
t(6;11)(q27;q23) KMT2A/MLLT4
t(6;7)(q23;q34) TRB/MYB and AHI1
t(7;10)(q34;q24) TRD/TLX1
t(7;11)(q35;p13) TBB/LMO2
t(7;12)(q34;p13) TRB/CCND2
t(7;14)(p15;q11) TRD/HOXA10
t(7;14)(q35;q32.1) TRB/TCL1A
t(7;19)(q34;p13) TRB/LYL1
t(7;7)(p15;q34) TRB/HOXA10
t(7;9)(q34;q32) TRB/TAL2
t(7;9)(q34;q34) TRB-NOTCH1
t(8;12)(q13;p13) ETV6/NCOA2
t(8;14)(q24;q11) TRA/MYC
t(8;21)(q24;q22) RUNX1/TRPS1
t(8;9)(p22;p24) PCM1/JAK2
t(9;12)(p24;p13) ETV6/JAK2
t(9;12)(q34;p13) ETV6/ABL1
t(9;14)(q34;q32) EML1/ABL1
t(9;22)(q34;q11) BCR/ABL1 in ALL
t(X;11)(q13;q23) KMT2A/FOXO4
t(X;7)(q22;q34) IRS4/TRB

7. Non Hodgkin Lymphomas (NHL)
Classification of B-cell non-Hodgkin's lymphomas (NHL)
+12 or trisomy 12
+18 or trisomy 18 in lymphoproliferative disorders
+20 or trisomy 20 (solely)
+3 or trisomy 3 in non Hodgkin's lymphoma (NHL)
+8 or trisomy 8
12p rearrangements in CLL
15q13-15 Rearrangements
1q triplication in hematologic malignancies
3q27 rearrangements (BCL6) in non Hodgkin lymphoma
ALK -positive diffuse large B-cell lymphoma
Anaplastic B-cell lymphoma
Anaplastic large cell lymphoma (ALCL)
Angioimmunoblastic T-cell lymphoma
Burkitt's lymphoma (BL)
Centroblastic lymphoma
Classification of B-cell non-Hodgkin lymphomas (NHL)
Classification of T-Cell disorders
Cutaneous T-cell lymphomas
Diffuse large cell lymphoma
Follicular lymphoma (FL)
Hepatosplenic T-cell lymphoma (HSTCL)
Hodgkin lymphoma
Immunoblastic lymphoma
Intestinal T-cell lymphoma
Lymphoepithelioid lymphoma
Lymphoplasmacytic lymphoma
Mantle cell lymphoma (incomplete)
Marginal Zone B-cell lymphoma
Mucosa-associated lymphoid tissue (MALT) lymphoma
Mycosis fungoides/Sezary's syndrome
NK cell neoplasias
Nasal T cell lymphoma
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
Primary cutaneous CD30+ anaplastic large cell lymphoma
Small lymphocytic lymphoma
T-cell large granular lymphocyte leukaemia
T-cell/histiocyte-rich large B cell lymphoma
Waldenstrom's macroglobulinemia (WM)
del (13q)
del(11q) in non-Hodgkin's lymphoma (NHL)
del(13q) in non-Hodgkin's lymphoma
del(17p) in non-Hodgkin's lymphoma (NHL)
del(3)(q27q27) ST6GAL1/BCL6
del(6q) abnormalities in lymphoid malignancies
del(7q) in non-Hodgkin's lymphoma (NHL)
dic(9;12)(p13;p13) PAX5/ETV6
ins(12;8)(p11;p12p22) FGFR1OP2/FGFR1
inv(14)(q11q32.1) TRA-TRD/TCL1A
inv(18)(p11q21)
inv(2)(p23q35) ATIC/ALK
inv(7)(p15q34) TRB/HOXA10
t(10;14)(q24;q11) TRD/TLX1
t(11;14)(q13;q32) IGH/CCND1
t(11;18)(q21;q21) BIRC3/MALT1
t(12;14)(p13;q32) IGK/CCND2
t(12;22)(p13;q11) IGL/CCND2
t(14;14)(q11;q32.1) TRA-TRD/TCL1A
t(14;15)(q32;q11) IGH/NBEAP1
t(14;18)(q32;q21) IGH/BCL2
t(14;18)(q32;q21) IGH/MALT1
t(14;19)(q32;q13) IGH/BCL3
t(14;22)(q32;q11) IGH/IGL
t(18;22)(q21;q11) IGL/BCL2
t(19;22)(q13;q11) BCL3/IGL
t(1;1)(p36;q21) in Non Hodgkin Lymphoma
t(1;13)(q32;q14)
t(1;14)(p22;q32) IGH/BCL10
t(1;14)(q21;q32)
t(1;14)(q21;q32) BCL9/IGH
t(1;14)(q21;q32) FCGR2B/IGH
t(1;14)(q21;q32) FCRL4/IGH
t(1;14)(q21;q32) MUC1/IGH
t(1;16)(q11;q11)
t(1;19)(q23;p13) TCF3/PBX1
t(1;2)(p22;p12) IGK/BCL10
t(1;2)(q25;p23) TPM3/ALK
t(1;22)(q21;q11)
t(1;22)(q21;q11) IGL/BCL9
t(1;3)(p36;p21)
t(1;3)(q25;q27) GAS5/BCL6
t(1;7)(q21;q22)
t(1;8)(p22-p32;q22-q23)
t(2;12)(p12;p13) IGH/CCND2
t(2;12)(q31;p13) ETV6/?
t(2;14)(p13-16;q32) IGH/BCL11A
t(2;17)(p23;q23) CLTC/ALK
t(2;17)(p23;q25) RNF213/ALK
t(2;18)(p11;q21) IGK/BCL2
t(2;18)(q11;q21) AFF3/BCL2
t(2;19)(p12;q13) IGK/BCL3
t(2;19)(p23;p13) TPM4/ALK
t(2;22)(p23;q11) CLTCL1/ALK
t(2;22)(p23;q11) MYH9-ALK
t(2;3)(p12;q27) IGK/BCL6
t(2;3)(p23;q21) TFG/ALK
t(2;5)(p23;q35) NPM1/ALK
t(2;5)(p23;q35) SQSTM1/ALK
t(2;6)(p12;p25) IRF4/IGK
t(2;8)(p12;q24) IGK/MYC
t(2;8)(p15;q24) BCL11A/MYC
t(3;11)(q27;q23) (NHL; BCL6 and OBF1, rare)
t(3;12)(q27;p12) LRMP/BCL6
t(3;12)(q27;p13) GAPDH/BCL6
t(3;13)(q27;q14) LCP1/BCL6
t(3;14)(p14;q32) IGH/FOXP1
t(3;14)(q21;q32)
t(3;14)(q27;q32) HSP90AA1/BCL6
t(3;14)(q27;q32) IGH/BCL6
t(3;16)(q27;p11) IL21R/BCL6
t(3;16)(q27;p13) CIITA/BCL6
t(3;19)(q27;q13) NAPA/BCL6
t(3;22)(q27;q11) IGL/BCL6
t(3;3)(q25;q27) MBNL1/BCL6
t(3;3)(q27;q27) ST6GAL1/BCL6
t(3;3)(q27;q28) EIF4A2/BCL6
t(3;3)(q27;q29) TFRC/BCL6
t(3;4)(q27;p13) RHOH/BCL6
t(3;6)(q27;p21)
t(3;6)(q27;p21) PIM1/BCL6
t(3;6)(q27;p21) SRSF3/BCL6
t(3;6)(q27;p22) HIST1H4I/BCL6
t(3;6)(q27;q14) SNHG5/BCL6
t(3;6)(q27;q15) ?/BCL6
t(3;7)(q27;p12) IKZF1-BCL6
t(3;7)(q27;q32) FRA7H/BCL6
t(3;7)(q27;q32) MIR29A/BCL6
t(3;8)(q27;q24) BCL6/MYC
t(3;9)(q26;p23) ?/MECOM
t(3;9)(q27;p13) GRHPR/BCL6
t(3;9)(q27;p24) DMRT1/BCL6
t(3;Var)(q27;Var) in non Hodgkin lymphoma
t(4;12)(p16;p13) ETV6/FGFR3
t(4;16)(q26;p13) IL2/TNFRSF17
t(5;9)(q33;q22) ITK/SYK
t(6;12)(p21;p13) CCND3/ETV6 in lymphoid malignancies
t(6;14)(p25.3;q11.2) TRA/IRF4
t(6;14)(p25;q32) IRF4/IGH
t(6;20)(q15;q11.2) BACH2/BCL2L1
t(6;22)(p25;q11) IRF4/IGL
t(6;7)(p25.3;q32.3) DUSP22/FRA7H
t(6;8)(q11;q11)
t(6;8)(q27;p12) FGFR1OP/FGFR1
t(7;10)(q34;q24) TRD/TLX1
t(7;14)(q35;q32.1) TRB/TCL1A
t(7;7)(p15;q34) TRB/HOXA10
t(7;8)(p12;q24) /MYC
t(8;12)(p12;p11) FGFR1OP2/FGFR1
t(8;12)(q24;p12) LRMP/MYC
t(8;13)(p11;q12) ZMYM2/FGFR1
t(8;14)(q24;q11) TRA/MYC
t(8;14)(q24;q32) IGH/MYC
t(8;22)(q24;q11) IGL/MYC
t(8;9)(p22;p24) PCM1/JAK2
t(8;9)(q24;p13) ?/MYC
t(8;9)(q24;q13)
t(9;14)(p13;q32) PAX5/IGH
t(X;14)(p11.4;q32.33) IGH/GPR34
t(X;2)(q11;p23) MSN/ALK

8. Chronic Lymphoproliferative Diseases (CLD)
Classification of B-cell chronic lymphoproliferative disorders (CLD)
+12 or trisomy 12
+15 or trisomy 15 (as sole autosomal abnormality)
+16 or trisomy 16 (solely)
+18 or trisomy 18 in lymphoproliferative disorders
+20 or trisomy 20 (solely)
+8 or trisomy 8
-21 or monosomy 21 (solely)
12p rearrangements in CLL
1q rearrangements in multiple myeloma
1q triplication in hematologic malignancies
Adult T-cell leukemia/lymphoma (ATLL)
B-cell prolymphocytic leukemia (B-PLL)
Chronic lymphocytic leukaemia (CLL)
Classification of B-cell chronic lymphoproliferative disorders (CLD)
Classification of T-Cell disorders
Fibrogenesis imperfecta ossium
Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia Variant (HCL-V)
Lymphomatoid papulosis (LyP) with 6p25.3 rearrangement DUSP22 and IRF4/
Multiple myeloma
Plasma cell leukemia (PCL)
Polyclonal B Lymphocytosis with Binucleated Lymphocytes (PPBL)
Splenic lymphoma with villous lymphocytes (SLVL)
T-cell prolymphocytic leukemia (T-PLL)
del (13q)
del(13q) in chronic lymphoproliferative diseases
del(13q) in multiple myeloma
del(6q) abnormalities in lymphoid malignancies
del(6q) in Multiple Myeloma
inv(14)(q11q32.1) TRA-TRD/TCL1A
inv(19)(p13q13) TCF3/TFPT
t(11;14)(p11;q32)
t(11;14)(q13;q32) IGH/CCND1
t(11;14)(q13;q32) IGH/CCND1 in multiple myeloma
t(13;19)(q14;p13) TCF3/?
t(14;14)(q11;q32.1) TRA-TRD/TCL1A
t(14;18)(q32;q21) IGH/BCL2
t(14;19)(q32;q13) IGH/BCL3
t(14;22)(q32;q11) IGH/IGL
t(18;22)(q21;q11) IGL/BCL2
t(19;19)(p13;q13) TCF3/TFPT
t(19;22)(q13;q11) BCL3/IGL
t(1;14)(q21;q32) FCRL4/IGH
t(1;3)(p36;q21) PSMD2/PRDM16
t(1;6)(p35;p25) ?/IRF4
t(1;6)(p36;p21)
t(2;14)(p13-16;q32) IGH/BCL11A
t(2;18)(p11;q21) IGK/BCL2
t(2;19)(p12;q13) IGK/BCL3
t(2;6)(p12;p25) IRF4/IGK
t(2;7)(p11;q21) IGK/CDK6
t(4;14)(p16;q32) IGH/FGFR3 and WHSC1
t(6;12)(p21;p13) CCND3/ETV6 in lymphoid malignancies
t(6;14)(p21;q32) IGH/CCND3
t(6;14)(p25;q32) IRF4/IGH
t(6;14)(q25-27;q32) BCL11B/?
t(6;22)(p21;q11)
t(6;22)(p25;q11) IRF4/IGL
t(7;14)(q21;q32) ERVW-1/IgH
t(7;14)(q21;q32) IGH/CDK6
t(7;14)(q35;q32.1) TRB/TCL1A
t(7;22)(q21;q11) IGL/CDK6
t(8;12)(q24;q22) BTG1/MYC
t(8;17)(q24;q22) ???BCL3/MYC
t(9;14)(p13;q32) PAX5/IGH
t(X;11)(q21;q23) BRWD3/ARHGAP20

9. Other

Castleman's disease

Home   Genes   Leukemias   Tumors   Cancer prone   Deep Insight   Case Reports   Portal   Journals   Teaching
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA